Gemcitabine plus axitinib was safer than gemcitabine alone.

The article discusses research being done on the safety of gemcitabine plus axitinib treatment regimen. It references a study by J. Spano and colleagues, published in the 2008 issue of "Lancet." The study examined the use of gemcitabine and axitinib in treating advanced pancreatic cancer. It randomly placed patients to either take combined gemcitabine and axitinib or gemcitabine alone. Study researchers concluded that combined therapy is safer than gemcitabine alone.